Brief: Gain Therapeutics Presents Preclinical Data Showing Potential Disease Modifying Benefits Of Novel Brain Penetrant Small Molecule Candidate GT-02287
19/09/2022 13:17
Sept 19 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS PRESENTS NEW PRECLINICAL DATA
DEMONSTRATING
POTENTIAL DISEASE MODIFYING BENEFITS OF ITS NOVEL BRAIN
PENETRANT SMALL MOLECULE CANDIDATE GT-02287 IN TWO PRECLINICAL
MODELS OF PARKINSON’S DISEASE
* GAIN THERAPEUTICS - TREATMENT WITH GT-02287 RESULTED IN
SIGNIFICANT DOSE-DEPENDENT IMPROVEMENT OF CELLULAR LYSOSOMAL
HEALTH AND FINE MOTOR SKILLS
Source text for Eikon: ID:nGNX6rVh31
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall